Terns Pharmaceuticals
Stock Forecast, Prediction & Price Target
Terns Pharmaceuticals (TERN) stock Price Target by analysts
$23
Potential upside: 264.49%
Terns Pharmaceuticals price prediction
What is Terns Pharmaceuticals stock analysts` prediction?
Terns Pharmaceuticals stock forecast: Based on 2 Wall Street analysts` predicted price targets for Terns Pharmaceuticals in the last 3 months, the avarage price target is $23, with a high forecast of $NaN. The average price target represents a 264.49% change from the last price of $6.31.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Terns Pharmaceuticals stock Price Target by analysts
Full breakdown of analysts given Terns Pharmaceuticals price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Jay Olson Oppenheimer | 0% 0/1 | 9 months ago | $20 216.95% upside | $6.36 | StreetInsider | Previous targets (0) |
Etzer Darout BMO Capital | 0% 0/2 | 12 months ago | $26 312.03% upside | $8.96 | TheFly | Previous targets (1) |
Graig Suvannavejh Mizuho Securities | 0% 0/1 | about 1 year ago | $10 58.47% upside | $7.79 | StreetInsider | Previous targets (0) |
Etzer Darout BMO Capital | 0% 0/2 | over 1 year ago | $19 201.10% upside | $7.2 | StreetInsider | Previous targets (1) |
Unknown H.C. Wainwright | N/A | over 2 years ago | $7 10.93% upside | $9.6 | Benzinga | N/A |
Unknown Goldman Sachs | N/A | over 2 years ago | $14 121.86% upside | $7.78 | Benzinga | N/A |
Corinne Jenkins Goldman Sachs | 100% 1/1 | almost 3 years ago | $9 42.62% upside | $4.92 | TheFly | Previous targets (0) |
Terns Pharmaceuticals Financial Estimates
Terns Pharmaceuticals Revenue Estimates
Terns Pharmaceuticals EBITDA Estimates
Terns Pharmaceuticals Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $1M N/A | $0 -100% | $0 0% | Avg: $2.17M Low: $2.17M High: $2.17M avg. 0% | Avg: $940K Low: $940K High: $940K avg. -56.71% | Avg: $18.1M Low: $18.1M High: $18.1M avg. 1825.53% | Avg: $19.65M Low: $19.65M High: $19.65M avg. 8.56% |
Net Income
% change YoY
| $-50.15M N/A | $-60.34M -20.30% | $-90.21M -49.49% | Avg: $-124.55M Low: $-135.39M High: $-65.25M avg. -38.07% | Avg: $-143.63M Low: $-111.16M High: $-38.88M avg. -15.31% | Avg: $-69.59M Low: $-69.59M High: $-69.59M avg. 51.54% | Avg: $-61.52M Low: $-61.52M High: $-61.52M avg. 11.60% |
EBITDA
% change YoY
| $-49.86M N/A | $-62.02M -24.40% | $-102.55M -65.33% | Avg: $1.30M Low: $1.30M High: $1.30M avg. 101.27% | Avg: $564K Low: $564K High: $564K avg. -56.71% | Avg: $10.86M Low: $10.86M High: $10.86M avg. 1825.53% | Avg: $11.79M Low: $11.79M High: $11.79M avg. 8.56% |
EPS
% change YoY
| -$1.98 N/A | -$1.67 15.65% | -$1.27 23.95% | Avg: -$1.39 Low: -$1.9 High: -$0.92 avg. -9.13% | Avg: -$1.24 Low: -$1.56 High: -$0.55 avg. 10.44% | Avg: -$0.98 Low: -$0.98 High: -$0.98 avg. 21.30% | Avg: -$0.86 Low: -$0.86 High: -$0.86 avg. 11.60% |
Operating Expenses
% change YoY
| $50.86M N/A | $62.02M 21.96% | $102.55M 65.33% | Avg: $10.22M Low: $10.22M High: $10.22M avg. -90.02% | Avg: $4.42M Low: $4.42M High: $4.42M avg. -56.71% | Avg: $85.24M Low: $85.24M High: $85.24M avg. 1825.53% | Avg: $92.54M Low: $92.54M High: $92.54M avg. 8.56% |
FAQ
What is Terns Pharmaceuticals stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 2.43% in 2025-2028.
We have gathered data from 5 analysts. Their low estimate is -135.39M, average is -124.55M and high is -65.25M.
What is Terns Pharmaceuticals stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 444.34% in 2025-2028.
We have gathered data from 7 analysts. Their low revenue estimate is $2.17M, average is $2.17M and high is $2.17M.
What is Terns Pharmaceuticals stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 8.55% in 2025-2028.
We have gathered data from 5 analysts. Their low earnings per share estimate is -$1.9, average is -$1.39 and high is $-0.91.
What is the best performing analyst?
In the last twelve months 2 analysts have been covering Terns Pharmaceuticals stock. The most successful analyst is Jay Olson.